હોમ › પ્રોસ્ટેટ કેન્સર › ઇલિનોઇસ › Chicago
Chicago, IL માં પ્રોસ્ટેટ કેન્સર ક્લિનિકલ ટ્રાયલ્સ
Chicago (લગભગ 30 માઇલની અંદર) ની સાઇટ્સ પર પ્રોસ્ટેટ કેન્સર માટે 45 અભ્યાસો ભાગીદારો શોધી રહ્યા છે. કોઈ અભ્યાસ ખોલો અને જુઓ કે કોઈ જોડાઈ શકે છે અને અભ્યાસ ટીમ સાથે સંપર્ક કેવી રીતે કરવો.
અધિકૃત અભ્યાસ ટેક્સ્ટ (અંગ્રેજી)
અહીં અભ્યાસ માટે ભરતી કરી રહ્યા છો? આ પેજની ટોચ પર તેને ફીચર કરો — 30 દિવસ માટે $99 →
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
ભરતી ચાલુ છેફેઝ 3
- Rush MD Anderson Cancer Center, Chicago
- University of Illinois, Chicago
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
ભરતી ચાલુ છેફેઝ 3
- Northwestern University, Chicago
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
ભરતી ચાલુ છેફેઝ 1
- University of Chicago Hospital, Chicago
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
ભરતી ચાલુ છેઅવલોકનકારી અભ્યાસસ્વસ્થ સ્વેચ્છાએ ભાગ લેનારા સ્વાગત છે
- Mount Sinai Hospital Medical Center, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
- University of Illinois, Chicago
- અને 1 વધુ
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
ભરતી ચાલુ છેફેઝ 2
- University of Illinois Cancer Center, Chicago
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
ભરતી ચાલુ છેફેઝ 2
- Rush MD Anderson Cancer Center, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
ભરતી ચાલુ છેફેઝ 2/3
- University of Chicago, Chicago
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
ભરતી ચાલુ છેફેઝ 3
- University of Illinois Chicago, Chicago
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
ભરતી ચાલુ છેફેઝ 3
- Northwestern University, Chicago
- University of Illinois Cancer Center at Chicago, Chicago
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
ભરતી ચાલુ છેફેઝ 3
- Research Site, Chicago
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
ભરતી ચાલુ છેફેઝ 3
- Rush University Medical Center-Hematology and Oncology ( Site 0028), Chicago
- University of Illinois at Chicago-University of Illinois Cancer Center ( Site 0063), Chicago
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
ભરતી ચાલુ છેફેઝ 3
- Northwestern University, Chicago
- University of Illinois, Chicago
- Advocate Illinois Masonic Medical Center, Chicago
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
ભરતી ચાલુ છેફેઝ 1
- University of Illinois Hospital & Health Sciences System, Chicago
MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy
ભરતી ચાલુ છે
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
ભરતી ચાલુ છેફેઝ 2
- University of Chicago Comprehensive Cancer Center, Chicago
A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss
ભરતી ચાલુ છેફેઝ 2
- Jesse Brown VA Medical Center, Chicago, IL, Chicago
A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
ભરતી ચાલુ છેફેઝ 1/2
- University of Chicago, Chicago
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
ભરતી ચાલુ છેફેઝ 3
- Northwestern University, Chicago
- Rush MD Anderson Cancer Center, Chicago
- University of Illinois, Chicago
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
ભરતી ચાલુ છેફેઝ 1
- University of Chicago Medical Center, Chicago
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
ભરતી ચાલુ છેફેઝ 1/2
- Research Site, Chicago
PSMA PET Combined With MRI for the Detection of PCa
ભરતી ચાલુ છેફેઝ 3સ્વસ્થ સ્વેચ્છાએ ભાગ લેનારા સ્વાગત છે
- UroPartners,LLC, Chicago
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
ભરતી ચાલુ છેફેઝ 3
- Rush MD Anderson, Chicago
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
ભરતી ચાલુ છેફેઝ 3
- University of Illinois, Chicago
Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
ભરતી ચાલુ છેફેઝ 2
- Northwestern University, Chicago
rhPSMA-73 PET-MRI Imaging for the Detection of Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance
ભરતી ચાલુ છેપ્રારંભિક ફેઝ 1સ્વસ્થ સ્વેચ્છાએ ભાગ લેનારા સ્વાગત છે
- Northwestern University, Chicago
Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation
ભરતી ચાલુ છેફેઝ 2
- UChicago Medicine Comprehensive Cancer Center, Chicago
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
ભરતી ચાલુ છેઅવલોકનકારી અભ્યાસ
- University of Illinois at Chicago, Chicago
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
- University of Chicago, Chicago
Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study
ભરતી ચાલુ છેઅવલોકનકારી અભ્યાસસ્વસ્થ સ્વેચ્છાએ ભાગ લેનારા સ્વાગત છે
- Northwestern, Chicago
A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
ભરતી ચાલુ છેફેઝ 1
- Research Site, Chicago
Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
ભરતી ચાલુ છેફેઝ 1/2
- Rush University, Chicago
Clinical Trial of Approaches to Prostate Cancer Surgery
ભરતી ચાલુ છે
- Northwestern University, Chicago
FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial
ભરતી ચાલુ છેફેઝ 2
- Northwestern University, Chicago
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
ભરતી ચાલુ છેફેઝ 1/2
- University of Chicago Medical Center, Chicago
Using MRI to Identify Areas to Receive Lower Doses of Radiation Treatment in Men With Prostate Cancerdose Mapping to Preserve Quality of Life
ભરતી ચાલુ છે
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
GU-01: Glycyrrhizin in Prostate Cancer
ભરતી ચાલુ છેફેઝ 2
- University of Illinois, Chicago
PSMA PET for Surveillance After Focal Therapy
ભરતી ચાલુ છે
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
ભરતી ચાલુ છેફેઝ 1
- The University of Chicago Comprehensive Cancer Center, Chicago
Prostate Ablation Registry and Database for Information, Surveillance, and Evaluation (PARADISE)
ભરતી ચાલુ છેઅવલોકનકારી અભ્યાસ
- The University of Chicago, Hyde Park · 5 માઇલ દૂર
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
ભરતી ચાલુ છેફેઝ 3
- Northwestern University, Chicago
- University of Illinois, Chicago
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
ભરતી ચાલુ છેફેઝ 4
- University of Chicago Medical Center, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
ભરતી ચાલુ છેઅવલોકનકારી અભ્યાસ
- Massive Bio SYNERGY-AI site, Chicago
Study to Assess the Feasibility of Stopping Prostate Cancer Treatment Early in Elderly Patients
ભરતી ચાલુ છે
- The University of Illinois at Chicago (UIC), Chicago
- UChicago Medicine Comprehensive Cancer Center, Chicago
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
ભરતી ચાલુ છેફેઝ 3
- Rush University Medical Center, Chicago
- University of Illinois, Chicago
Geriatric Assessment and Technology Evaluation in Prostate Cancer
ભરતી ચાલુ છેઅવલોકનકારી અભ્યાસ
- o University of Chicago Medicine Comprehensive Cancer Center, Chicago
Anti-inflammatory Drugs and Serum Prostate-Specific Antigen Test
ભરતી ચાલુ છેફેઝ 4
- University of Chicago Medical Center, Chicago
અન્ય શહેરોમાં પ્રોસ્ટેટ કેન્સર ટ્રાયલ્સ
- New York City, NY103 અભ્યાસો
- Houston, TX76 અભ્યાસો
- Los Angeles, CA61 અભ્યાસો
- Boston, MA59 અભ્યાસો
- St. Louis, MO46 અભ્યાસો
- San Francisco, CA45 અભ્યાસો
- Philadelphia, PA44 અભ્યાસો
- Baltimore, MD43 અભ્યાસો
- Nashville, TN42 અભ્યાસો
- Seattle, WA42 અભ્યાસો
- Washington, DC38 અભ્યાસો
- Dallas, TX36 અભ્યાસો
Chicago માં અન્ય અભ્યાસો
- નોન-સ્મોલ સેલ લંગ કેન્સર61 અભ્યાસો
- સ્તન કેન્સર58 અભ્યાસો
- કેન્સર (બધા પ્રકાર)51 અભ્યાસો
- મેટાસ્ટેટિક કેન્સર45 અભ્યાસો
- સ્થૂળતા41 અભ્યાસો
- ફેફસાનું કેન્સર41 અભ્યાસો
- ઓવેરિયન કેન્સર36 અભ્યાસો
- સ્ટ્રોક34 અભ્યાસો
- કોલોરેક્ટલ કેન્સર33 અભ્યાસો
- હૃદય અપૂરતાપણું31 અભ્યાસો
- ઓવરવેઇટ28 અભ્યાસો
- માથું અને ગળાનો સ્ક્વેમસ સેલ કાર્સિનોમા26 અભ્યાસો
ClinicalTrials.gov પરથી, તારીખ 5 ઑક્ટો, 2026 ના ડેટા સાથે. દરેક અભ્યાસની પોતાની પાત્રતા શરતો હોય છે; અભ્યાસ ટીમ નક્કી કરે છે કે કોઈ જોડાઈ શકે છે કે નહીં.